IRadimed Corporation (IRMD) Financial Ratios

IRadimed Corporation (IRMD) has an ST Score of 58.4 out of 100, an overall grade of B-. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Wall Street's consensus rating on IRMD is Buy based on 2 analyst ratings. Our own ST Score grades it B- (58.4/100). This is data, not investment advice — always do your own research.

IRadimed Corporation (IRMD) earns a valuation grade of F, measured against Medical - Devices peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

IRadimed Corporation (IRMD) earns a growth grade of B, measured against Medical - Devices peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

IRadimed Corporation (IRMD) earns a profitability grade of A, measured against Medical - Devices peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

IRadimed Corporation (IRMD) earns a financial strength grade of A+, measured against Medical - Devices peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for IRadimed Corporation (IRMD) is $100.00 from 2 analysts, which is +0.2% versus the recent price of $86.51.

IRadimed Corporation (IRMD) has a Piotroski F-Score of 5 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.